What is a biomarker? from its discovery to clinical application

Journal of Medical Biochemistry

Volumn 30, Issue 3, 2011, Pages 186-192

  Majkić Singh, Nada ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

biomarkers; clinical significance; definition; discovery

Indexed keywords

BIOLOGICAL MARKER; MOLECULAR MARKER; PROTEIN;

ARTICLE; CLINICAL CHEMISTRY; CLINICAL LABORATORY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE COURSE; DISEASE SEVERITY; HUMAN; PRACTICE GUIDELINE; PREDICTIVE VALUE; PROGNOSIS; REFERENCE VALUE; RELIABILITY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS;

EID: 79959546268     PISSN: 14528258     EISSN: 14528266     Source Type: Journal    
DOI: 10.2478/v10011-011-0029-z     Document Type: Article

References (34)

1. Biomarkers Definition Working Group. Biomarkers and su rrogate end-point: preferred definitions and con ceptual frame work. Clin Pharmacol Ther 2001; 69: 89-95.
2. Manolio T. Novel Risk markers and clinical practice. N Engl J Med 2003; 349: 1587-9. (Pubitemid 37288564)
3. Dickstein K, Cohen-Solal A, Filippatos G, et al. for the Task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur Heart J 2008; 29: 2388-2442.
4. Felker GM, Hasselblad V, Hernandet A, OConnor CM. Biomarker-guided therapy in chronic heart failure. A meta-analysis of randomized controlled trials. Am Heart J 2009; 158: 422-30.
5. Vasan RS. Biomarkers of cardiovascular disease: molecular basis and practical consideration. Circulation 2006; 113: 2335-62. (Pubitemid 43947980)
6. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, et al. Improving the quality of reporting of ran do -mized controlled trials: the CONSORT statement. JAMA 1996; 276: 637-9. (Pubitemid 26278070)
7. Bossuyt PM, Reitdma JB, Bruns DE, Gatsonis CA, Glas -ziou PP, Irwig LM, Moher D, et al. The STARD Sta te ment for Reporting Studies of Diagnostic Accuracy: Expla nation and Elaboration. Clin Chem 2003; 49: 7-18. (Pubitemid 36078547)
8. Evidence-Based Medicine Working Group. Evidencebased medicine: a new approach to the teaching of medicine. JAMA 1992; 268: 2420-5.
9. Wolf SH, Grol R, Hutchinson A, Eccles M, Grimshaw J, et al. Clinical guidelines: potential benefits, limitations, and harms of clinical guidelines. BMJ 1999; 318: 527-30. (Pubitemid 29189000)
10. Majkić-Singh N. Biochemical indicators of acute co -ronary syndrome. Acta Clinica 2010; 10: 34-51.
11. Bossuyt MMP. Defining biomarker performance and clinical validity. Journal of Medical Biochemistry 2011;30: 193-200.
12. Gillery P. Nonenzymatic post-translational modification derived products (PTMDPS): New biomarkers of protein aging. Journal of Medical Biochemistry 2011;30: 201-6.
13. Sypniewska G, Bergmann K, Krintus M, Kozinski M, Kubica J. How do apolipoproteins ApoB and ApoA-I perform in patients with acute coronary syndromes. Journal of Medical Biochemistry 2011;30: 237-43.
14. Aslan D. Biomarkers for diabetes complications: The results of several clinical studies. Journal of Medical Biochemistry 2011;30: 207-12.
15. Janković M. Glycans as biomarkers: Status and per spec ti -ves. Journal of Medical Biochemistry 2011;30: 213-23.
16. Ptolomey SA, Rifai N. What is a biomarker? Research investments and lack of clinical integration necessitate a review of biomarker terminology and validation sche ma. Scand J Clin Lab Invest 2010; 70 (Suppl 242): 3: 6-14.
17. Food and Drug Administration, Department of Health and Human Service. Approval based on a surrogate endp oint or on an effect on a clinical endpoint other than survival or irreversible morbidity, 2009: 5: 21CFR314.510.
18. Loukopoulos P, Shibata T, Katoh H, Kokubu A, at al. Ge nome-wide array-based comparative genomic hybri -di zation analysis of pancreatic adenocarcinoma: Iden ti -fication of genetic indicators that predict patient out -come. Cancer Science 2007; 98: 392-400. (Pubitemid 46195611)
19. Ritcher W. Imaging biomarkers as surrogate endpoints for drug development. Eur J Nucl Med Mol Imaging 2006; 33: S6-10.
20. Sargent DJ, Rubinstein L, Schwartz L. Validation of no -vel imaging methodologies for use as cancer clinical trial end-points. Eur J Cancer 2009; 45: 290-9.
21. Cai W, Chen X. Multimodality molecular imaging of tu -mor angiogenesis. J Nucl Med 2008, 49: 113-28.
22. Ransohoff DF. How to improve reliability and efficiency of research about molecular markers: roles of phases, guidelines, and study design. J Clin Epidemiolog 2007; 60: 1205-19. (Pubitemid 350061148)
23. Pepe MS, Feng Z, Janes H, Bossuyt PM, PoterJD. Pi -votal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J Natl Cancer Inst 2008; 100: 1432-8.
24. Bossuyt PM, Reitsma JB, Burns DE, Gatsonis CA, Glas -ziou PP, Irwig LM, et al. Towards complete and accu -rate reporting of studies of diagnostic accuracy: the STARDT initiative. Ann Intern Med 2003; 138: 40-4. (Pubitemid 36232093)
25. Van Walraven C, Naylor D. Do we know what inap pro -priate laboratory utilization is? A systematic review of l -boratory audits. JAMA 1998; 280: 550-8. (Pubitemid 28377676)
26. Price CP. Improving the quality of peer reviewed lite -rature on diagnostic tests: the STARD initiative. (Guest Editorial). Clin Chim Acta 2003; 334: 1-3. (Pubitemid 36836055)
27. Sackett DL, Richardson WS, Rosenberg W, Haynes RB. Evi dence-based medicine: how to practice and teach EBM. Edinburg, Scotland: Churchill Livingstone, 2000; 261pp.
28. Wolf SH, Grol R, Hutchinson A, Eccles M, Grimshaw J, et al. Clinical guidelines: potential benefits, limitations, and harms of clinical guidelines. BMJ 1999; 318: 527-30. (Pubitemid 29189000)
29. Altman DG. Better reporting of randomized controlled trials: the CONSORT statement. Authors must provide enough information for readers to know how the trial was performed Editorial. BMJ 1996; 313: 570-1.
30. Balk E. Heart Disease. In: Evidence-based medicine. Optimizing Decision-Making to Improve Patient Care. Proceedings of the Evidence-Based Medicine Confe -rence. May 19-20, 2000 Washington, DC, 20-3.
31. Vittorini S, Clerico A. Cardiovascular biomarkers: in cre -a sing impact of laboratory medicine in cardiology practice. Clin Chem Lab Mad 2008; 46: 748-63. (Pubitemid 351821652)
32. Vasan S. Biomarkers of cardiovascular disease: mole cu -lar basis and practical considerations. Circulation 2006; 113: 2335-62.
33. Christenson HR, Azzazy EM. Biomarkers of Myocardial Necrosis: Past, Present, and Future. In: Cardiovascular Biomarkers, Pathophysiology and Disease Mana ge -ment, Ed. By David A. Morrow, Humana Press, 2006, 3-25.
34. Horvath RA, Kis A, Dobos E. Guidelines for the use of biomarkers: Principles, processes and practical consi de -rations. Scand J Clin Lab Invest 2010; 70 (Suppl 242): 109-16.